at 52 Weeks MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions 1 The study also showed people living with obesity or overweight and Type 2 diabetes, who typically lose less weight on GLP-1 therapies, achieved up to ~17% average weight loss, also without a weight loss plateau, and lowered their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52
If youre considering a GLP-1, your healthcare team can help you understand how it fits into your overall health plan and what benefits you can expect
Some protocols involve continuous administration for 6-12 months with periodic assessment and dose adjustment
A new understanding has emerged
So it seems to have a very good effect on the cells in the blood vessels
With numerous wellness clinics providing this service, it is essential to understand what sets MDRN Wellness apart